Magnetic Resonance Imaging Study of Cognitive-Behavior Therapy for Major Depressive Disorder
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT01460212 |
Recruitment Status : Unknown
Verified September 2014 by Chun Wang, Nanjing Medical University.
Recruitment status was: Recruiting
First Posted : October 26, 2011
Last Update Posted : September 25, 2014
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Major Depressive Disorder | Drug: SSRI antidepressants Behavioral: Cognitive-Behavior Therapy | Phase 4 |
Study Type : | Interventional (Clinical Trial) |
Estimated Enrollment : | 80 participants |
Allocation: | Randomized |
Intervention Model: | Parallel Assignment |
Masking: | None (Open Label) |
Primary Purpose: | Treatment |
Official Title: | Magnetic Resonance Imaging Study of Cognitive-Behavior Therapy for Major Depressive Disorder |
Study Start Date : | December 2011 |
Estimated Primary Completion Date : | December 2014 |
Estimated Study Completion Date : | October 2015 |

Arm | Intervention/treatment |
---|---|
Experimental: Cognitive-Behavior Therapy group
treatment with Cognitive-Behavior Therapy
|
Behavioral: Cognitive-Behavior Therapy
The essence of CBT is a learning process through which an appropriate pattern in cognitive and behavioral could be learn and stored as memory
Other Name: cognitive behavioural therapy(CBT) |
Active Comparator: SSRI antidepressants
treatment by SSRI antidepressant
|
Drug: SSRI antidepressants
SSRI antidepressants are Selective serotonin reuptake inhibitors. They include fluoxetine (Prozac); sertraline (Zoloft); paroxetine (Paxil); citalopram (Celexa) ;escitalopram (Lexapro) and fluvoxamine (Luvox). It will be chosen according to special condition of every patient.
Other Names:
|
- Hamilton Rating Scale for Depression (HAMD) [ Time Frame: an expected average of 6 months ]The 24-item version of the Hamilton Rating Scale for Depression (HAMD; Hamilton, 1960) will be used for measuring severity of depressive symptoms. Minimum and maximum possible values are respectively 0 and 78. Lower scores show more mild depression.
- Magnetic Resonance Imaging [ Time Frame: an expected average of 6 months ]

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 20 Years to 50 Years (Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | Yes |
Inclusion Criteria:
- meet SCID -Ⅰ/P major depressive disorder diagnosis;
- Right handedness;
- good visual acuity.
Exclusion Criteria:
- neurological disease ;
- serious physical illness (e.g. heart, lung, liver, kidney or blood system disease);
- with other mental disorder;
- psychotic symptoms
- personality disorders;
- pregnancy;
- suicidal risk;
- treatment by antidepressants or other psychotropic medications within 6 months prior to the start of the trial;
- with contraindication for MRI

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01460212
Contact: Chun Wang, doctor | 86 15850566376 | fm51109@163.com |
China, Jiangsu | |
Nanjing Brain Hospital | Recruiting |
Nanjing, Jiangsu, China, 210029 | |
Principal Investigator: Chun Wang |
Principal Investigator: | Chun Wang, doctor | Nanjing Medical University |
Responsible Party: | Chun Wang, The attending physician, Dr., Nanjing Medical University |
ClinicalTrials.gov Identifier: | NCT01460212 |
Other Study ID Numbers: |
QYK09184 |
First Posted: | October 26, 2011 Key Record Dates |
Last Update Posted: | September 25, 2014 |
Last Verified: | September 2014 |
Cognitive-Behavior Therapy Magnetic Resonance Imaging major depressive disorder |
Disease Depressive Disorder Depression Depressive Disorder, Major Pathologic Processes Mood Disorders Mental Disorders Behavioral Symptoms Fluvoxamine Citalopram Fluoxetine Paroxetine Sertraline Antidepressive Agents Serotonin Uptake Inhibitors |
Neurotransmitter Uptake Inhibitors Membrane Transport Modulators Molecular Mechanisms of Pharmacological Action Neurotransmitter Agents Serotonin Agents Physiological Effects of Drugs Antidepressive Agents, Second-Generation Psychotropic Drugs Cytochrome P-450 CYP2D6 Inhibitors Cytochrome P-450 Enzyme Inhibitors Enzyme Inhibitors Anti-Anxiety Agents Tranquilizing Agents Central Nervous System Depressants Cytochrome P-450 CYP1A2 Inhibitors |